GW572016

A drug used to treat HER2 positive (HER2+) breast cancer that is advanced or has spread to other parts of the body. It is used with capecitabine in patients whose cancer has not gotten better with other anticancer drugs. It is used with letrozole in postmenopausal women whose cancer is hormone receptor positive (HR+) and who need hormone therapy. It is also being studied in the treatment of other types of cancer. GW572016 blocks epidermal growth factor receptor (EGFR) and other proteins, which may help keep cancer cells from growing. GW572016 is a type of ErbB2 and EGFR dual tyrosine kinase inhibitor. Also called lapatinib, lapatinib ditosylate, and Tykerb.

• Dailymed label info on GW572016
• FDA GW572016

GW572016 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski